Recombinant Nerve Growth Factor antibody

Catalog No. ABIN7543390

This anti-Nerve Growth Factor antibody is a Rabbit Chimeric antibody detecting Nerve Growth Factor in ELISA, BP, Crys, in vitro, in vivo and Inh. Suitable for Human.

Quick Overview for Recombinant Nerve Growth Factor antibody (ABIN7543390)

Target: Nerve Growth Factor (NGF)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Chimeric

Conjugate: This Nerve Growth Factor antibody is un-conjugated

Application: ELISA, Blocking Peptide (BP), Crystallization (Crys), In vitro Assay (in vitro), In vivo Studies (in vivo), Inhibition (Inh)

Clone: 911

Product Details anti-Nerve Growth Factor Antibody

Purpose: Anti-Nerve growth factor [mab 911], Rabbit IgG, kappa

Specificity: The antibody is specific for NGF. The NGF epitope is composed of β-strand segments from both NGF monomers. NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons).

Cross-Reactivity: Mouse

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Isotype: IgG kappa

Application Details

Application Notes: The specificity of the original format of the antibody to NGF was confirmed by ELISA analysis (EC50 = 0.37 nM). The antibody was evaluated for its ability to block the binding of hNGF to the TrkA and p75 NGF receptors in various in vitro assays, such as blocking of TrkA autophosphorylation and blocking of NGF-dependent survival of dorsal root ganglion sensory neurons. The antibody was a potent blocker of all activities (Hongo et al., 2000, PMID: 10952410). In vivo administration of the antibody significantly reduces bone cancer pain behaviors (Sevcik et al., 2005, PMID: 15836976 and Halvorson et al., 2005, PMID: 16230406 and Buehlmann et al., 2019, PMID: 30161041) and fracture pain-related behaviors (Koewler et al., 2007, PMID: 17638576). The structure of Nerve Growth factor in complex with the Fab fragment was determined. Library Scanning Mutagenesis method was used to convert the original antibody in the humanized antibody tanezumab. The antibody bound human and murine NGF with high affinity (KD ~10 nM). Tanezumab and the original antibody blocked both TrkA and p75NTR binding to NGF and inhibited NGF-dependent neuron survival. Tanezumab inhibited NGFdependent survival with an IC50 of 15 pM, under the same conditions, 911 inhibited NGF with an IC50 of 400 pM (La Porte et al., 2014, PMID: 24830649). Preventative and therapeutic treatment with the antibody significantly prevented, or reversed, MIA-induced pain behaviour in osteoarthritis (Xu et al., 2016, PMID: 27208420).

Comment:

This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for Nerve Growth Factor

Target: Nerve Growth Factor (NGF)

Alternative Name: Nerve growth factor

Background: Beta-nerve growth factor, Beta-NGF

UniProt: P01138

Pathways: Regulation of Cell Size